Dianthus Therapeutics Inc. Common Stock (DNTH)

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendri…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

92

Website

dianthustx.com/

Fundamentals

1-day range

$105.6$111.31

Market cap

$5.80B

P/E (trailing)

—

P/E (forward)

-22.31

EPS (trailing)

$-4.15

Dividend yield

—

Beta

1.86

Avg. volume

1.06M

Forecasts

13 analyst ratings

Dianthus Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• DNTH

  Dianthus Therapeutics Inc. Common Stock

  $105.72

  ▼ 5.22%
  Market cap $5.80BP/E —
  $22.81$117.88
• LGND

  Ligand Pharmaceuticals Incorporated Common Stock

  $280

  ▼ 1.59%
  Market cap $5.85BP/E 38.07
  $158.4$326.63
• KNSA

  Kiniksa Pharmaceuticals International plc Class A Ordinary Shares

  $78.1

  ▼ 2.13%
  Market cap $5.73BP/E 75.29
  $33.25$82.94
• PTCT

  PTC Therapeutics Inc. Common Stock

  $70.01

  ▼ 2.51%
  Market cap $5.68BP/E —
  $48.86$90.87
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28
• GRFS

  Grifols S.A. American Depositary Shares

  $7.68

  ▼ 1.79%
  Market cap $5.40BP/E 13.31
  $8.43$12.87

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
  SeekingAlpha · 8/25/2026
• Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
  Benzinga · 8/6/2026
• HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
  Benzinga · 8/6/2026
• Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
  Benzinga · 8/5/2026
• Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate
  Benzinga · 8/4/2026
• Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027
  Benzinga · 8/4/2026
• Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134
  Benzinga · 8/3/2026

• Adam M. Veness · August 13, 2026 · Option Exercise

  15.0K @ $18.17
• Anne McGeorge · August 10, 2026 · Option Exercise

  6.5K @ $11.2
• Anne McGeorge · August 10, 2026 · Option Exercise

  1.3K @ $19.36
• Anne McGeorge · August 10, 2026 · Sale

  700 @ $111.41
• Anne McGeorge · August 10, 2026 · Sale

  1.0K @ $110.64
• Anne McGeorge · August 10, 2026 · Sale

  1.8K @ $109.3
• Anne McGeorge · August 10, 2026 · Sale

  2.8K @ $108.38
• Anne McGeorge · August 10, 2026 · Sale

  1.4K @ $107.58
• Adam M. Veness · August 10, 2026 · Option Exercise

  16.2K @ $17.88
• Adam M. Veness · August 10, 2026 · Sale

  16.2K @ $110.38
• Simon Read · August 10, 2026 · Option Exercise

  2.8K @ $18.36
• Simon Read · August 10, 2026 · Sale

  397 @ $111.77
• Simon Read · August 10, 2026 · Sale

  470 @ $111.05
• Simon Read · August 10, 2026 · Sale

  272 @ $109.96
• Simon Read · August 10, 2026 · Sale

  831 @ $108.95

Institutional Ownership

March 31, 2026

Total shares held

61.85M

Total value held

$4.92B

Institutional holders

236